Media headlines about Oncobiologics (NASDAQ:ONS) have trended somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Oncobiologics earned a news sentiment score of 0.20 on Accern’s scale. Accern also gave media headlines about the company an impact score of 45.035017323751 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
A number of equities research analysts have recently issued reports on ONS shares. ValuEngine upgraded Oncobiologics from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Barclays lowered Oncobiologics from an “overweight” rating to an “equal weight” rating in a research note on Monday, January 29th. One analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $9.00.
Oncobiologics (ONS) traded down $0.03 during mid-day trading on Thursday, hitting $1.14. The stock had a trading volume of 30,584 shares, compared to its average volume of 57,644. The company has a quick ratio of 0.14, a current ratio of 0.14 and a debt-to-equity ratio of -0.40. Oncobiologics has a fifty-two week low of $0.78 and a fifty-two week high of $3.77.
WARNING: This piece of content was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://sportsperspectives.com/2018/02/08/oncobiologics-ons-receiving-somewhat-positive-media-coverage-study-shows.html.
Oncobiologics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform.
Receive News & Ratings for Oncobiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics and related companies with MarketBeat.com's FREE daily email newsletter.